Division of Gastroenterology, University of Alberta, 2-14A Zeidler Building, Edmonton, AB T6G 2X8, Canada.
Gastroenterol Clin North Am. 2010 Sep;39(3):543-57. doi: 10.1016/j.gtc.2010.08.018.
In the last 10 years, anti-tumor necrosis factor (TNF)-α therapy has become a cornerstone in the management of autoimmune diseases. Clinical trial data have consistently found that infliximab, adalimumab, and recently certolizumab pegol offer therapeutic benefits to patients with inflammatory bowel diseases (Crohn's disease and ulcerative colitis). Recent understanding on how these monoclonal antibodies evoke changes at the physiological and molecular levels have provided insights into disease pathogenesis and helped to identify new targets for future drug therapy. With increased experience in the use of these anti-TNF-α antibodies the long-term safety data, use in pregnancy have become available. This article provides an overview of the current knowledge regarding anti-TNF-α therapies for clinicians caring for patients with Crohn's disease and ulcerative colitis.
在过去的 10 年中,抗肿瘤坏死因子(TNF)-α 治疗已成为治疗自身免疫性疾病的基石。临床试验数据一致表明,英夫利昔单抗、阿达木单抗和最近的培塞利珠单抗为炎症性肠病(克罗恩病和溃疡性结肠炎)患者提供了治疗益处。最近对这些单克隆抗体如何在生理和分子水平上引起变化的了解,为疾病发病机制提供了新的认识,并有助于确定未来药物治疗的新靶点。随着使用这些抗 TNF-α 抗体经验的增加,长期安全性数据和在妊娠期间的使用数据也已变得可用。本文为治疗克罗恩病和溃疡性结肠炎患者的临床医生提供了关于抗 TNF-α 治疗的最新知识概述。